Related Experiment Video
Updated: Oct 19, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Tackling PARP inhibitor resistance
Kasper Fugger1, Graeme Hewitt1, Stephen C West1
1The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Homologous recombination-deficient (HRD) tumors show sensitivity to poly(ADP-ribose) polymerase inhibitors (PARPis). Genetic screens reveal new targets to overcome PARPi resistance in HRD cancers.
Area of Science:
- Oncology
- Cancer Genetics
- DNA Repair Mechanisms
Background:
- Homologous recombination-deficient (HRD) tumors, including those with BRCA mutations, are sensitive to poly(ADP-ribose) polymerase inhibitors (PARPis).
- Most HRD cancers develop resistance to PARPi treatment via reversion mutations or alterations in DNA repair pathways.
- Overcoming PARPi resistance is crucial for improving treatment efficacy in HRD cancers.
Purpose of the Study:
- To review recent genetic screening insights identifying novel therapeutic targets.
- To discuss strategies for enhancing PARPi potency and overcoming resistance in HRD cancers.
Main Methods:
- Review of recent genetic screening studies.
- Analysis of identified genes and their role in DNA repair pathways.
Main Results:
- Genetic screens have identified several novel genes that can be targeted.
- These targets may offer a means to overcome acquired resistance to PARPi therapy.
- Targeting these pathways could enhance the effectiveness of PARPi treatment.
Conclusions:
- Targeting newly identified genes represents a promising strategy to improve PARPi therapy for HRD cancers.
- These strategies may help overcome resistance and improve patient outcomes.
More Related Videos
15:53Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...